Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma

Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma

Opis bibliograficzny
Główni autorzy:	Couillard, S, Pavord, ID
Format:	Journal article
Język:	English
Wydane:	Wiley 2022

Podobne zapisy

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
od: Harsha H Kariyawasam, i wsp.
Wydane: (2010-06-01)

Efficacy of Mometasone Furoate and Fluticasone Furoate on Persistent Allergic Rhinoconjunctivitis
od: W. Hamizan Aneeza M.S., i wsp.
Wydane: (2013-09-01)

Effect of fluticasone propionate/formoterol and fluticasone furoate/vilanterol on adolescents with chronic bronchial obstruction
od: Tiina Helena Tanninen, MD, i wsp.
Wydane: (2024-08-01)

Fluticasone furoate nasal spray in the treatment of allergic rhinitis
od: Pedro Giavina-Bianchi, i wsp.
Wydane: (2008-04-01)

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience
od: Timothy E. Albertson, i wsp.
Wydane: (2016-02-01)

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
od: Jacques Loretta, i wsp.
Wydane: (2011-10-01)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
od: Woodcock Ashley, i wsp.
Wydane: (2011-12-01)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
od: Ryo Atsuta, i wsp.
Wydane: (2018-10-01)

Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial
od: George Bardsley, i wsp.
Wydane: (2018-07-01)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
od: Nicola C. Day, i wsp.
Wydane: (2020-06-01)

Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo.
od: Nan Zhang, i wsp.
Wydane: (2014-01-01)

A Patient Preference Study that Evaluated Fluticasone Furoate and Mometasone Furoate Nasal Sprays for Allergic Rhinitis
od: Anahi Yanez M.D., i wsp.
Wydane: (2016-10-01)

Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis
od: Maria Doulaptsi, i wsp.
Wydane: (2021-09-01)

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
od: Covelli H, i wsp.
Wydane: (2015-12-01)

In vitro Antibacterial Activity of Mometasone Furoate, Fluticasone Propionate and Fluticasone Furoate Nasal Preparations Against Streptococcus pneumoniae, Hemophilus influenzae, Streptococcus viridans, Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli
od: Philip Lance A. Liu, i wsp.
Wydane: (2010-06-01)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
od: Peter R. Bremner, i wsp.
Wydane: (2018-01-01)

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
od: Bogart M, i wsp.
Wydane: (2023-12-01)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
od: Bernstein David I, i wsp.
Wydane: (2011-12-01)

Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate
od: Högger Petra, i wsp.
Wydane: (2007-07-01)

Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation
od: Hamouda M, i wsp.
Wydane: (2023-07-01)

Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study
od: Daniel Dedman, i wsp.
Wydane: (2019-04-01)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma.
od: Pavord, I, i wsp.
Wydane: (2007)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
od: Woodcock Ashley, i wsp.
Wydane: (2007-09-01)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
od: Yoxall Sally, i wsp.
Wydane: (2007-07-01)

Efficacy and safety of fluticasone furoate nasal spray in adult and adolescent subjects with uncomplicated acute rhinosinusitis
od: Keith Paul, i wsp.
Wydane: (2011-11-01)

Comparative study of the efficacy and safety of intranasal azelastine hydrochloride and fluticasone furoate in the treatment of allergic rhinitis
od: Nandish Chennakeshavaraju, i wsp.
Wydane: (2020-01-01)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
od: Molino A, i wsp.
Wydane: (2018-06-01)

Fluticasone furoate nasal spray: Profile of an enhanced-affinity corticosteroid in treatment of seasonal allergic rhinitis
od: Robert Anolik
Wydane: (2010-08-01)

Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma
od: Bernstein David I, i wsp.
Wydane: (2010-12-01)

Fluticasone Propionate in Inflammatory Bowel Disease
od: Marta Carpani de Kaski, i wsp.
Wydane: (1990-01-01)

Effects of Salmeterol and Fluticasone Propionate Combination versus Fluticasone Propionate on Airway Function and Eosinophilic Inflammation in Mild Asthma
od: Makoto Hoshino, i wsp.
Wydane: (2009-01-01)

Comparison of Budesonide/formoterol versus Fluticasone furoate/vilanterol as maintenance and reliever therapy for asthma control: a real-world observational study
od: Wei-Chun Huang, i wsp.
Wydane: (2024-08-01)

Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma
od: Roberto W. Dal Negro, i wsp.
Wydane: (2018-09-01)

Fixed combination of vilanterol triphenatate/fluticasone furoate in the treatment of patients with bronchial asthma and chronic obstructive pulmonary disease: a literature review
od: A. A. Viesel, i wsp.
Wydane: (2022-01-01)

A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
od: Courtney Crim, i wsp.
Wydane: (2020-05-01)

Fluticasone furoate induced iatrogenic Cushing syndrome in a pediatric patient receiving anti-retroviral therapy
od: S A A van den Berg, i wsp.
Wydane: (2017-04-01)

Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial
od: Peter Daley-Yates, i wsp.
Wydane: (2022-09-01)

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study
od: Henrik Watz, i wsp.
Wydane: (2020-04-01)

A comparative study of fluticasone propionate, mometasone furoate, and saline nasal spray in the treatment of children with adenoid hypertrophy}
od: Gurbax Singh, i wsp.
Wydane: (2023-01-01)

Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS
od: Vallejo-Aparicio LA, i wsp.
Wydane: (2018-09-01)